Peak Asset Management LLC acquired a new position in Bristol Myers Squibb Company (NYSE:BMY – Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 32,175 shares of the biopharmaceutical company’s stock, valued at approximately $1,854,000.
A number of other institutional investors have also bought and sold shares of BMY. Life Cycle Investment Partners Ltd acquired a new stake in shares of Bristol Myers Squibb in the fourth quarter valued at $34,406,000. Lazard Asset Management LLC increased its stake in shares of Bristol Myers Squibb by 23.7% during the first quarter. Lazard Asset Management LLC now owns 1,924,036 shares of the biopharmaceutical company’s stock worth $116,693,000 after acquiring an additional 368,193 shares during the period. Axxcess Wealth Management LLC raised its position in Bristol Myers Squibb by 27.4% in the fourth quarter. Axxcess Wealth Management LLC now owns 98,665 shares of the biopharmaceutical company’s stock worth $5,322,000 after acquiring an additional 21,196 shares in the last quarter. BlackRock Inc. lifted its stake in shares of Bristol Myers Squibb by 5.1% in the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock valued at $10,393,783,000 after purchasing an additional 8,702,106 shares during the period. Finally, Asset One Wealth Management LLC acquired a new position in Bristol Myers Squibb during the fourth quarter worth $4,075,000. 76.41% of the stock is owned by hedge funds and other institutional investors.
Bristol Myers Squibb Stock Performance
NYSE BMY opened at $67.30 on Tuesday. The business’s 50-day simple moving average is $60.77 and its 200-day simple moving average is $59.47. The firm has a market capitalization of $137.47 billion, a P/E ratio of 14.82, a P/E/G ratio of 0.17 and a beta of 0.22. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $68.64. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38.
Bristol Myers Squibb Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd were given a $0.63 dividend. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 annualized dividend and a yield of 3.7%. Bristol Myers Squibb’s dividend payout ratio (DPR) is 55.51%.
Analysts Set New Price Targets
Several analysts have recently commented on the stock. BMO Capital Markets reiterated a “market perform” rating on shares of Bristol Myers Squibb in a research report on Monday, July 27th. Weiss Ratings upgraded Bristol Myers Squibb from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, August 18th. Argus raised Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 price target on the stock in a research note on Wednesday, August 5th. Piper Sandler assumed coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They issued an “overweight” rating for the company. Finally, Raymond James Financial initiated coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a “strong-buy” rating on the stock. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Bristol Myers Squibb presently has an average rating of “Moderate Buy” and a consensus target price of $66.06.
Check Out Our Latest Research Report on BMY
Bristol Myers Squibb Profile
Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.
BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.
Read More
- Five stocks we like better than Bristol Myers Squibb
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.
